Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy

被引:60
|
作者
Li, Qian [1 ,2 ]
Kim, Jongphil [3 ]
Balagurunathan, Yoganand [2 ]
Liu, Ying [1 ]
Latifi, Kujtim [4 ]
Stringfield, Olya [2 ]
Garcia, Alberto [2 ]
Moros, Eduardo G. [2 ,4 ]
Dilling, Thomas J. [4 ]
Schabath, Matthew B. [5 ]
Ye, Zhaoxiang [1 ]
Gillies, Robert J. [2 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Radiol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
关键词
computed tomography; image features; radiomics; semantics; stereotactic body radiotherapy (SBRT); survival; POSITRON-EMISSION-TOMOGRAPHY; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; PROGNOSTIC-FACTOR; VESSEL INVASION; RADIOMICS; RECURRENCE; IMPACT; REPRODUCIBILITY; IMAGES;
D O I
10.1002/mp.12309
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To investigate whether imaging features from pretreatment planning CT scans are associated with overall survival (OS), recurrence-free survival (RFS), and loco-regional recurrence-free survival (LR-RFS) after stereotactic body radiotherapy (SBRT) among nonsmall-cell lung cancer (NSCLC) patients. Patients and methods: A total of 92 patients (median age: 73 yr) with stage I or IIA NSCLC were qualified for this study. A total dose of 50 Gy in five fractions was the standard treatment. Besides clinical characteristics, 24 "semantic" image features were manually scored based on a point scale (up to 5) and 219 computer-derived "radiomic" features were extracted based on whole tumor segmentation. Statistical analysis was performed using Cox proportional hazards model and Harrell's C-index, and the robustness of final prognostic model was assessed using tenfold cross validation by dichotomizing patients according to the survival or recurrence status at 24 months. Results: Two-year OS, RFS and LR-RFS were 69.95%, 41.3%, and 51.85%, respectively. There was an improvement of Harrell's C-index when adding imaging features to a clinical model. The model for OS contained the Eastern Cooperative Oncology Group (ECOG) performance status [Hazard Ratio (HR) = 2.78, 95% Confidence Interval (CI): 1.37-5.65], pleural retraction (HR = 0.27, 95% CI: 0.08-0.92), F2 (short axis x longest diameter, HR = 1.72, 95% CI: 1.21-2.44) and F186 (HistEnergy- L1, HR = 1.27, 95% CI: 1.00-1.61); The prognostic model for RFS contained vessel attachment (HR = 2.13, 95% CI: 1.24-3.64) and F2 (HR = 1.69, 95% CI: 1.33-2.15); and the model for LR-RFS contained the ECOG performance status (HR = 2.01, 95% CI: 1.12-3.60) and F2 (HR = 1.67, 95% CI: 1.29-2.18). Conclusions: Imaging features derived from planning CT demonstrate prognostic value for recurrence following SBRT treatment, and might be helpful in patient stratification. (C ) 2017 American Association of Physicists in Medicine
引用
收藏
页码:4341 / 4349
页数:9
相关论文
共 50 条
  • [21] Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy
    Tahir, Ismail
    Marquardt, J. Peter
    Mercaldo, Nathaniel D.
    Bourgouin, Patrick P.
    Wrobel, Maria M.
    Mrah, Sofiane
    Sharp, Gregory C.
    Khandekar, Melin J.
    Willers, Henning
    Keane, Florence K.
    Fintelmann, Florian J.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2022, 219 (04) : 579 - 589
  • [22] Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point
    Kotha, Nikhil, V
    Cherry, Daniel R.
    Bryant, Alex K.
    Nalawade, Vinit
    Stewart, Tyler F.
    Rose, Brent S.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 28 : 133 - 140
  • [23] Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy
    Shintani, Takashi
    Matsuo, Yukinori
    Iizuka, Yusuke
    Mitsuyoshi, Takamasa
    Mizowaki, Takashi
    Hiraoka, Masahiro
    ANTICANCER RESEARCH, 2017, 37 (09) : 5161 - 5167
  • [24] Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience
    Song, Xue
    Zhao, Lijun
    Jiang, Ning
    Ding, Naixin
    Zong, Dan
    Zhang, Nan
    Wang, Dejun
    Wen, Jing
    He, Xia
    Kong, Cheng
    Zhu, Xiangzhi
    CURRENT PROBLEMS IN CANCER, 2023, 47 (03)
  • [25] Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy
    Zhang, Ran
    Wang, Changbin
    Cui, Kai
    Chen, Yicong
    Sun, Fenghao
    Sun, Xiaorong
    Xing, Ligang
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9921 - 9929
  • [26] Identification of novel prognostic factors focusing on clinical outcomes in patients with non-small cell lung cancer after stereotactic body radiotherapy
    Sato, Hikari
    Ito, Fumiki
    Hasegawa, Kazuki
    Saga, Ryo
    Hosokawa, Yoichiro
    Tanaka, Mitsuki
    Aoki, Masahiko
    ONCOLOGY LETTERS, 2022, 23 (03)
  • [27] Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative analysis
    Detillon, Deniece D. E. M. A.
    Aarts, Mieke J.
    De Jaeger, Katrien
    Van Eijck, Casper H. J.
    Veen, Eelco J.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (06)
  • [28] Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system
    Katoh, Norio
    Soda, Itaru
    Tamamura, Hiroyasu
    Takahashi, Shotaro
    Uchinami, Yusuke
    Ishiyama, Hiromichi
    Ota, Kiyotaka
    Inoue, Tetsuya
    Onimaru, Rikiya
    Shibuya, Keiko
    Hayakawa, Kazushige
    Shirato, Hiroki
    RADIATION ONCOLOGY, 2017, 12
  • [29] Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy
    Oikonomou, Anastasia
    Khalvati, Farzad
    Tyrrell, Pascal N.
    Haider, Masoom A.
    Tarique, Usman
    Jimenez-Juan, Laura
    Tjong, Michael C.
    Poon, Ian
    Eilaghi, Armin
    Ehrlich, Lisa
    Cheung, Patrick
    SCIENTIFIC REPORTS, 2018, 8
  • [30] Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer
    Shibamoto, Yuta
    Hashizume, Chisa
    Baba, Fumiya
    Ayakawa, Shiho
    Manabe, Yoshihiko
    Nagai, Aiko
    Miyakawa, Akifumi
    Murai, Taro
    Iwata, Hiromitsu
    Mori, Yoshimasa
    Mimura, Mikio
    Ishikura, Satoshi
    CANCER, 2012, 118 (08) : 2078 - 2084